8-K: Checkpoint Therapeutics Completes Acquisition by Sun Pharma, Delists from Nasdaq

Checkpoint Therapeutics, Inc. has finalized its merger with Sun Pharmaceutical Industries, Inc., becoming a wholly-owned subsidiary and delisting from Nasdaq, with shareholders receiving $4.10 cash per share plus a contingent value right.

Summary

• Checkpoint Therapeutics, Inc. (CKPT) completed its merger with Snoopy Merger Sub, Inc., a wholly-owned subsidiary of Sun Pharmaceutical Industries, Inc. (Sun Pharma), on May 30, 2025.
• As a result of the merger, Checkpoint Therapeutics is now a wholly-owned subsidiary of Sun Pharma.
• Each share of Checkpoint Therapeutics common stock outstanding immediately prior to the merger was converted into the right to receive $4.10 in cash and one non-tradable contingent value right (CVR).
• The CVR represents the right to receive a contingent cash payment of up to $0.70 per share, conditioned upon the achievement of a specified regulatory milestone for cosibelimab (UNLOXCYT) in the European Union or certain key European countries.
• The potential CVR payments range from $0.20 to $0.70, depending on the timing of the milestone achievement and the approved dosing schedule (once every three weeks vs. more frequent).
• Trading of Checkpoint Therapeutics common stock on The Nasdaq Stock Market LLC was suspended prior to the opening of trading on May 30, 2025, and the company intends to delist and deregister its common stock.
• Immediately prior to the merger's closing, certain material definitive agreements, including the Amended and Restated Founders Agreement and the Management Services Agreement with Fortress Biotech, Inc., and the Board Advisory Services Agreement with Caribe BioAdvisors, LLC, were automatically terminated.

Sentiment

Score: 7

Explanation: The completion of the merger provides a definitive cash payout to shareholders and retains potential upside through a CVR, which is generally positive for investors seeking liquidity and a defined return. While the CVR's value is uncertain, the primary transaction is complete as expected, reducing market uncertainty for the company's future.

Positives

• Shareholders received a guaranteed cash payment of $4.10 per share, providing immediate liquidity and a defined return on their investment.
• Shareholders retain potential upside through a non-tradable Contingent Value Right (CVR) of up to $0.70 per share, tied to the regulatory approval of cosibelimab in Europe.
• The acquisition by Sun Pharma, a larger pharmaceutical company, provides the Product (cosibelimab) with potentially greater resources for late-stage development, regulatory navigation, and commercialization in Europe.
• The merger provides a clear exit strategy for Checkpoint Therapeutics shareholders, resolving the company's standalone future.

Negatives

• Checkpoint Therapeutics common stock has been delisted from Nasdaq, removing its public trading status and liquidity for shareholders.
• The CVRs are non-tradable, limiting shareholders' ability to realize their value before the milestone is achieved or expires.
• There is no assurance that the CVR milestone will be achieved or that any contingent payments will be made, introducing uncertainty for the full potential value of the CVRs.
• The company's independent operations and strategic direction are now fully controlled by Sun Pharma, ending its status as a standalone public entity.

Risks

• There is no assurance that the Milestone for cosibelimab's regulatory approval in Europe will be achieved on or before the Milestone Deadline Date (36 months after EMA positive validation outcome), or that any Milestone Payments will be made.
• The amount of the CVR payment is contingent on both the timing of the milestone achievement and the approved dosing schedule (once every three weeks vs. more frequent), introducing variability in potential returns.
• Parent's obligation to use 'Commercially Reasonable Efforts' to achieve the Primary Milestone does not guarantee success and is subject to various factors including regulatory feedback and additional trial requirements.
• The CVRs are non-transferable, meaning holders cannot sell them on an open market, limiting liquidity and the ability to exit the contingent payment exposure.

Future Outlook

Sun Pharmaceutical Industries, Inc. (Parent) is obligated to use commercially reasonable efforts to file a marketing authorization application (MAA) for cosibelimab (UNLOXCYT) with the European Medicines Agency (EMA) within 12 months of the closing date, or as promptly as practicable thereafter if feedback from the EMA makes it inadvisable to file within that timeframe. Parent is also committed to using commercially reasonable efforts to achieve the Primary Milestone (EU centralized approval) as promptly as practicable, including timely appeals and curing deficiencies. However, there is no assurance that the milestone will be achieved or that any contingent payments will be made.

Management Comments

• The Company (Checkpoint Therapeutics) intends to file with the SEC a certification on Form 15 under the Exchange Act, requesting the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act and the termination of registration of the Common Stock under Section 12(g) of the Exchange Act.

Industry Context

This acquisition reflects a broader trend of consolidation within the biotechnology and pharmaceutical sectors, where larger companies acquire smaller, clinical-stage firms to gain access to promising drug candidates like cosibelimab. Such mergers allow the acquiring entity to leverage its extensive resources for late-stage development, regulatory navigation, and commercialization, while providing an exit and potential upside for the acquired company's shareholders.

Comparison to Industry Standards

• N/A. This document details the completion of a specific acquisition and does not provide performance metrics or product comparisons against industry benchmarks or specific comparable companies/projects. The focus is on the transaction terms and post-merger corporate status.

Management Changes

Corporate Governance

Related Party Transactions

• Termination of the Amended and Restated Founders Agreement, dated July 11, 2016, between Fortress Biotech, Inc. and the Company.
• Termination of the Management Services Agreement, dated March 17, 2015, between Fortress Biotech, Inc. and the Company.
• Termination of the Board Advisory Services Agreement, dated January 1, 2017, between the Company and Caribe BioAdvisors, LLC, due to the departure of Michael S. Weiss from the board.

Stakeholder Impact

• Shareholders: Received a fixed cash payment of $4.10 per share and a non-tradable contingent value right (CVR) of up to $0.70 per share, providing immediate liquidity and potential future upside. However, they lose direct equity ownership and the ability to trade the company's stock on a public exchange.
• Employees: Key management roles have changed, with new directors and officers appointed from Sun Pharmaceutical Industries, Inc.'s subsidiary. The broader impact on other employees is not detailed but is typical in acquisitions.
• Customers/Suppliers: No direct impact mentioned in the filing, but the change in ownership may lead to integration of operations and supply chains under Sun Pharma.
• Creditors: The aggregate transaction consideration was funded through Parent's available cash on hand, suggesting no new debt for the acquisition, which is generally neutral to positive for creditors.

Next Steps

• The Company will file a Form 15 with the SEC to suspend its reporting obligations and terminate the registration of its common stock.
• Sun Pharmaceutical Industries, Inc. will use commercially reasonable efforts to pursue regulatory approval for cosibelimab (UNLOXCYT) in Europe to achieve the CVR milestone.
• The Rights Agent will distribute CVR payments to holders if the milestone is achieved.

Key Dates

Keywords

Checkpoint Therapeutics, Sun Pharmaceutical Industries, Merger, Acquisition, CVR, Contingent Value Right, Cosibelimab, UNLOXCYT, Biotechnology, Pharmaceutical, SEC Filing, 8-K, Delisting, Corporate Governance, Drug Development, Regulatory Approval, EMA, Nasdaq